Contineum Therapeutics (CTNM) Cantor Global Healthcare Conference 2025 summary

Company overview and strategic focus

• Focuses on neuroscience, inflammation, and immunology, leveraging overlapping targets in these areas.

• Two clinical-stage assets: PIPE-307 (M1 receptor antagonist) and PIPE-791 (LPA1 receptor antagonist).

• Emphasizes early de-risking of assets through clinical validation and receptor occupancy studies.

• Collaborates with J&J on PIPE-307 for MDD and MS indications.

• Four major clinical readouts expected over the next 12 months.

PIPE-791 program and IPF landscape

• IPF affects about 130,000 in the US and 3 million globally, with current treatments considered suboptimal due to efficacy and tolerability issues.

• PIPE-791 targets the LPA1 receptor, aiming for improved efficacy, safety, and dosing convenience.

• The molecule features a slow on/off rate, blunted peak-to-trough, and high receptor occupancy, potentially enhancing tolerability.

• A global phase 2 proof-of-concept study is set to initiate in Q4, designed for robust efficacy and safety comparison to BMS’s program.

• PET receptor occupancy study readout is expected in Q3 to validate dose selection.

Expansion into pain and MS indications

• PIPE-791 is also being explored in chronic pain and progressive MS, with the MS study postponed to prioritize the large IPF trial.

• The pain study is a phase 1B exploratory trial in osteoarthritis and chronic lower back pain, focusing on non-opioid alternatives.

• LPA is implicated in the pathophysiology of IPF, pain, and MS, linking these indications through inflammation and demyelination mechanisms.

• Top-line data from the pain study is expected in the first half of next year.